Filtered By:
Condition: Disability
Drug: Prozac

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 28 results found since Jan 2013.

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
CONCLUSIONS: We found no reliable evidence that SSRIs should be used routinely to promote recovery after stroke. Meta-analysis of the trials at low risk of bias indicate that SSRIs do not improve recovery from stroke. We identified potential improvements in disability only in the analyses which included trials at high risk of bias. A further meta-analysis of large ongoing trials will be required to determine the generalisability of these findings. PMID: 31769878 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 25, 2019 Category: General Medicine Authors: Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

Podcast: Selective serotonin reuptake inhibitors for stroke recovery
Stroke is a major cause of death and disability across the world, with many reviews from the Cochrane Stroke Group providing evidence on the effects of treatments and rehabilitation interventions. In November 2019, the Group published their update of their review of selective serotonin reuptake inhibitors and we asked lead author, Gillian Mead from the University of Edinburgh in Scotland, to tell us more.Stroke is a common cause of disability in the community. Although there have been major advances in the care of stroke patients over the last few years, many survivors are still left with physical disability, such as weakn...
Source: Cochrane News and Events - February 26, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Pharmacological interventions and rehabilitation approach for enhancing brain self-repair and stroke recovery.
Abstract Neuroplasticity is a natural process occurring in the brain for entire life. Stroke is the leading cause of long term disability and huge medical and financial problem throughout the world. Research conducted over the past decade focused mainly on neuroprotection in the acute phase of stroke while very little studies targets chronic stage. Recovery after stroke depends on the ability of our brain to reestablish structural and functional organization of neurovascular networks. Combining adjuvant therapies and drugs may enhance the repair processes and restore impaired brain functions. Currently, there are ...
Source: Current Neuropharmacology - July 24, 2019 Category: Drugs & Pharmacology Authors: Szelenberger R, Kostka J, Saluk-Bijak J, Miller E Tags: Curr Neuropharmacol Source Type: research

Interventions for post-stroke fatigue.
CONCLUSIONS: There was insufficient evidence on the efficacy of any intervention to treat or prevent fatigue after stroke. Trials to date have been small and heterogeneous, and some have had a high risk of bias. Some of the interventions described were feasible in people with stroke, but their efficacy should be investigated in RCTs with a more robust study design and adequate sample sizes. PMID: 26133313 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - July 2, 2015 Category: Journals (General) Authors: Wu S, Kutlubaev MA, Chun HY, Cowey E, Pollock A, Macleod MR, Dennis M, Keane E, Sharpe M, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials
DiscussionIf fluoxetine is safe and effective in promoting functional recovery, it could be rapidly, widely and affordably implemented in routine clinical practice and reduce the burden of disability due to stroke.Trial registrationFOCUS: ISRCTN83290762 (23/05/2012), AFFINITY: ACTRN12611000774921 (22/07/2011). EFFECTS: ISRCTN13020412 (19/12/2014).
Source: Trials - August 20, 2015 Category: Journals (General) Authors: Gillian MeadMaree HackettErik LundströmVeronica MurrayGraeme HankeyMartin Dennis Source Type: research

A commonly-used antidepressant doesn ' t improve recovery after stroke
The antidepressant fluoxetine works no better than placebo to reduce disability after a stroke, lowering hopes that had been raised by other smaller studies. After a six month trial including more than 3,000 adult stroke patients recruited at 103 UK hospitals, researchers concluded that fluoxetine should not be used to promote recovery from stroke-related disability, or routinely prescribed to prevent depression after stroke. Several smaller studies and animal trials had found promising results from the use of fluoxetine after stroke. However, this trial of fluoxetine 20mg daily for six months found no improvement in funct...
Source: Current Awareness Service for Health (CASH) - February 18, 2019 Category: Consumer Health News Source Type: news

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial.
CONCLUSION: There was no significant difference between citalopram and fluoxetine in facilitating post-stroke motor recovery in ischemic stroke patients. However, compared with a placebo, both drugs improved post-stroke motor function. PMID: 29783900 [PubMed - as supplied by publisher]
Source: Clinical Rehabilitation - May 1, 2018 Category: Rehabilitation Authors: Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E Tags: Clin Rehabil Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
CONCLUSIONS: There is high-quality evidence that SSRIs do not make a difference to disability or independence after stroke compared to placebo or usual care, reduced the risk of future depression, increased bone fractures and probably increased seizure risk.PMID:34780067 | DOI:10.1002/14651858.CD009286.pub4
Source: Cochrane Database of Systematic Reviews - November 15, 2021 Category: General Medicine Authors: Lynn A Legg Ann-Sofie Rudberg Xing Hua Simiao Wu Maree L Hackett Russel Tilney Linnea Lindgren Mansur A Kutlubaev Cheng-Fang Hsieh Amanda J Barugh Graeme J Hankey Erik Lundstr öm Martin Dennis Gillian E Mead Source Type: research

Treatments for Poststroke Motor Deficits and Mood Disorders: A Systematic Review for the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Stroke Rehabilitation.
Conclusion: Cardiorespiratory training, repetitive task training, and transcranial direct current stimulation may improve ADLs in adults with stroke. Cognitive behavioral therapy, exercise, and SSRIs may reduce symptoms of poststroke depression, but use of SSRIs to prevent depression or improve motor function was not supported. Primary Funding Source: U.S. Department of Veterans Affairs, Veterans Health Administration. PMID: 31739315 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - November 18, 2019 Category: Internal Medicine Authors: D'Anci KE, Uhl S, Oristaglio J, Sullivan N, Tsou AY Tags: Ann Intern Med Source Type: research

Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic
Conclusion: Among patients with stroke, early initiation of fluoxetine did not result in improved functional recovery. Lower rates of depression were observed in the fluoxetine-treated group; however these patients experienced higher rates of bone fracture.
Source: The Neurologist - May 1, 2021 Category: Neurology Tags: Critically Appraised Topics Source Type: research

Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ConclusionsAdministration of SSRIs may improve gross motor function, reduce disability and enhance QOL for patients recovering from stroke.
Source: Clinical Drug Investigation - July 29, 2017 Category: Drugs & Pharmacology Source Type: research

Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis.
Conclusions: Paroxetine is probably the best option to consider for patients with PSD. To get a quicker relief of depression, duloxetine might be useful for its rapid onset of antidepressant action. The tolerability was comparable among all the antidepressants. But more high-quality RCTs are needed. PMID: 29805769 [PubMed]
Source: Oncotarget - May 31, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Fluoxetine for Stroke: A Mixed Bag of Outcomes
J Clin Psychiatry. 2021 Jun 8;82(3):21f14106. doi: 10.4088/JCP.21f14106.ABSTRACTStroke is the leading neurologic cause of burden operationalized in terms of disability-adjusted life-years. After stroke, motor deficits, cognitive deficits, and depression cause loss of independence, disability, decreased functioning, and reduced quality of life; these persist into the long term. There are theoretical grounds to consider that, through neuroplasticity and other mechanisms, such impairments can be prevented or attenuated by the early introduction of a selective serotonin reuptake inhibitor such as fluoxetine. However, a recent ...
Source: Journal of Clinical Psychiatry - June 9, 2021 Category: Psychiatry Authors: Chittaranjan Andrade Source Type: research